Stocktoria
Humacyte, Inc. HUMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-22
Chart by TradingView
3/9
Piotroski F — financial health
-23.79
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $2.0M | $0 | — | — | — |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M | -$81.2M |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M | -$26.5M |
| Operating cash flow | -$105.0M | -$98.1M | -$73.3M | -$71.1M | -$81.2M |
| Free cash flow | -$105.9M | -$99.7M | -$75.6M | -$72.2M | -$81.4M |
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $164.4M |
| Shareholders' equity | $3.1M | -$52.7M | $13.5M | $116.9M | $122.2M |
| Ratios | |||||
| Operating margin | -5306.0% | — | — | — | — |
| Net margin | -2003.6% | — | — | — | — |
| FCF margin | -5197.5% | — | — | — | — |
| Return on assets | -35.1% | -107.9% | -86.4% | -5.9% | -9.2% |
| Return on equity | -1313.4% | 282.3% | -817.8% | -10.2% | -21.7% |
| Debt / equity | 11.40× | -0.00× | — | — | 0.25× |
| Current ratio | 3.69 | 2.40 | 4.52 | 7.88 | 20.75 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -23.79 (distress)
- Working capital / assets 0.425
- Retained earnings / assets -6.246
- EBIT / assets -0.929
- Equity / liabilities 0.027
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001818382 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.